AnaptysBio, Inc. ANAB 深 滬
已收盤 01-09 16:00:00 美东时间
44.67
+0.870
+1.99%
華盛通- 最 高46.2678
- 今 開42.75
- 成交量 59.18万股
- 最 低 42.50
- 昨 收 43.80
- 總市值 12.37亿
- 52周最高 52.47
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 12.21
- 委 比 32.89%
- 總股本 2768.85万
- 歷史最高 134.00
- 量 比 0.77
- 振 幅 8.60%
- 歷史最低 10.00
- 每 手 1
- 風險率 9.48%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多AnaptysBio Pushes Back Against Lawsuit Over Cancer Drug Jemperli Royalties
AnaptysBio asks a Delaware court to dismiss Tesaro's breach claim, citing anti-SLAPP law in a dispute over Jemperli royalties and licensing rights.
01-10 02:56
SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director
SAB Biotherapeutics announced the appointments of David Zaccardelli, Pharm.D., as Chair of its Board of Directors, and Rita Jain, M.D., as an independent director. Both bring extensive expertise in biopharma and autoimmune disease development. Reich highlighted their contributions to growing companies and creating shareholder value. Zaccardelli emphasized the potential of SAB-142 for T1D, while Jain praised the company’s innovative approach to tr...
01-07 13:00
Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference
AnaptysBio, Inc. announced that CEO Daniel Faga will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 4:30pm PT. The presentation will be live-streamed on the company's investor website, with a replay available for 30 days. AnaptysBio focuses on innovative immunology therapeutics for autoimmune and inflammatory diseases, with a pipeline including rosnilimab, ANB033, and ANB101. The company has licensed therapeu...
01-06 21:15
美股大行评级 | 德银首予Coinbase"买入"评级，目标价340美元；AERO获多家机构首予超配评级；大摩维持苹果"超配"评级，目标价升至315美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从9美元升至10美元；摩根大通：上调Recursion Pharmaceuticals评级至"超配"，目标价从10美元升至11美元
2025-12-18 10:54
美股大行评级 | 绩后分化！甲骨文遭14家大行集体下调目标价；新思科技、Planet获多家机构上调目标价！
今日重点评级关注：HC Wainwright & Co.：维持Moleculin Biotech"买入"评级，目标价从4美元升至22美元；HC Wainwright & Co.：上调Soluna Holdings评级至"买入"，目标价5美元
2025-12-12 10:24
Stifel Maintains Buy on AnaptysBio, Lowers Price Target to $56
Stifel analyst Alex Thompson maintains AnaptysBio (NASDAQ:ANAB) with a Buy and lowers the price target from $80 to $56.
2025-12-11 21:17
Wall Street Analysts Are Bullish on Top Healthcare Picks
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts jus...
2025-12-11 20:20
SA Quant ranks Goldman's small-cap stocks with largest short interest
Goldman Sachs analysts last week identified 50 small-cap stocks with the highest short interest as a percentage of market cap, a list that was topped by Anavex Life Sciences (AVXL). The brokerage look...
2025-11-27 04:13
Anaptys Announces Participation in December Investor Conferences
AnaptysBio announced that its leadership team will participate in upcoming investor conferences, including the Piper Sandler 37th Annual Healthcare Conference on Dec. 2, 2025, and the Evercore 8th Annual Healthcare Conference on Dec. 3, 2025. The events will feature fireside chats and one-on-one meetings. The company focuses on innovative immunology therapeutics for autoimmune and inflammatory diseases, with key pipeline candidates including rosn...
2025-11-25 21:15
美股大行评级 | 摩根大通上调百度至"超配"，目标价升至188美元！Navan获多家机构首予"买入"评级，目标价最高30美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从4美元升至9美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从32美元升至38美元
2025-11-25 10:27
